Table 1.

Patients characteristics at the beginning of the study (group A).

Group A	Age (years)	Sex	Diagnosis	Therapy	Dose1	Hb2	Epo3	Cr4
Patient 1	60	M	Head and neck cancer	Cisplatin	100	149	10.23	74.3
				5-Fluorouracil	2000
Patient 2	55	F	Head and neck cancer	Carboplatin	45	111	12.00	54.8
Patient 3	60	M	Head and neck cancer	Cisplatin	100	137	14.29	69.0
				5-Fluorouracil	2000
Patient 4	67	F	Head and neck cancer	Carboplatin	580	155	9.11	Missing
				Paclitaxel	175
Patient 5	56	M	Head and neck cancer	Carboplatin	580	148	9.39	109.6
				Paclitaxel	175
Patient 6	60	F	Ovarian carcinoma	Carboplatin	580	111	32.82	73.4
				Paclitaxel	175
Patient 7	67	M	Head and neck cancer	Cisplatin	80	156	8.10	63.6
Patient 8	63	F	Head and neck cancer	Cisplatin	80	139	5.58	53.9
				5-Fluorouracil	1600
Patient 9	59	M	Colon-rectal cancer	Cisplatin	80	154	20.07	76.0
				5-Fluorouracil	1600
Patient 10	43	F	Colon-rectal cancer	Carboplatin	700	166	5.94	77.8
				Paclitaxel	175
Patient 11	68	M	Head and neck cancer	Cisplatin	100	145	11.90	119.3
				5-Fluorouracil	2000
Patient 12	63	M	Head and neck cancer	Carboplatin	45	136	8.07	65.4
Patient 13	73	F	Ovarian carcinoma	Carboplatin	400	119	20.03	81.3
				Paclitaxel	175
Patient 14	54	M	Head and neck cancer	Cisplatin	100	147	41.13	44.2
				5-Fluorouracil	2000
Patient 15	36	F	Head and neck cancer	Cisplatin	100	107	15.29	62.8
				5-Fluorouracil	2000
Mean						138.67	14.93	73.2
Median						145.00	11.90	71.2
s.d.						18.48	10.09	20.3

¹Dose mg/m²

²Hb g/l

³Erythropoietin (Epo) mU/ml

⁴Creatinine (Cr) μmol/l.